VYNE Therapeutics

What VYNE Therapeutics does

VYNE Therapeutics is a clinical-stage biopharmaceutical company developing proprietary therapies for immuno-inflammatory conditions through its InhiBET BET Inhibitor Platform, which targets bromo-domain and extra-terminal domain (BET) proteins involved in regulation of inflammatory and oncogenic genes. The pipeline consists of two candidates licensed from Tay Therapeutics: Repibresib (VYN201), a locally administered pan-BD BET inhibitor gel being developed primarily for nonsegmental vitiligo; and VYN202, an oral BD2-selective BET inhibitor for immune-mediated diseases including plaque psoriasis. In July 2025, Repibresib's Phase 2b vitiligo trial did not meet its primary or key secondary endpoints, and in April 2025 the FDA placed a clinical hold on VYN202's Phase 1b psoriasis trial following observed testicular toxicity in dogs (partially lifted for female patients).

The company has no commercial products and minimal operating revenue, consisting almost entirely of royalty payments from LEO Pharma on the licensed Finacea foam franchise (~$0.2 million per quarter). With $39.6 million in cash as of June 30, 2025, VYNE has limited standalone runway. In December 2025, VYNE announced an all-stock merger with Yarrow Bioscience valued at approximately $200 million, expected to close in Q2 2026, under which pre-merger VYNE stockholders will retain only ~3% of the combined entity, which will operate as Yarrow Bioscience (ticker YARW) and focus on YB-101 for Graves' disease and thyroid eye disease. The combined company is expected to be funded into 2028 by ~$200 million in pre-closing private financings led by RTW Investments.

Name

VYNE Therapeutics

Legal name

VYNE Therapeutics Inc.

Website

https://vynetherapeutics.com

Company type

Public

Founded year

2019

Operating status

Operating

Headcount range

11–50 employees

Short description

VYNE Therapeutics is a clinical-stage biopharmaceutical company developing BET inhibitor therapies (Repibresib, VYN202) for immuno-inflammatory diseases, with no commercial revenue beyond LEO Pharma royalties and a pending all-stock merger into Yarrow Bioscience (expected to close Q2 2026).

Ownership category

akta.pro rank

Product category

Immuno-inflammatory Therapeutics

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Immunology & Inflammation Pharmaceuticals (HLAIAAAD)

akta.pro secondary industries

Immunology & Autoimmune Specialty Pharmaceuticals (HLAIACAB), Endocrinology & Reproductive Health Pharmaceuticals (incl. Women’s Health) (HLAIAAAJ)

Keywords

• BET inhibitor therapeutics
• Immuno-inflammatory treatments
• Clinical-stage biopharmaceutical
• Dermatology drug development
• Small molecule therapies

Headquarters

HQ city

Menlo Park

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Others

Revenue model

1. Royalty Revenue: VYNE receives royalty revenue from its licensing agreement with LEO Pharma for Finacea foam. Royalty revenues were approximately $0.2 million per quarter in 2025.
2. Merger with Yarrow Bioscience: VYNE agreed to merge with Yarrow Bioscience in an all-stock transaction valued at approximately $200 million. Pre-closing financings of approximately $200 million are expected to fund operations into 2028. The combined company will focus on YB-101 for Graves' disease and thyroid eye disease.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels5 records

Core offering

VYNE Therapeutics is a clinical-stage biopharmaceutical company developing proprietary BET (bromo-domain and extra-terminal domain) inhibitor therapies for immuno-inflammatory conditions. Its lead candidates are Repibresib (VYN201), a topical pan-BD BET inhibitor gel for nonsegmental vitiligo, and VYN202, an oral BD2-selective BET inhibitor for plaque psoriasis and other autoimmune diseases. All assets are investigational; the company currently generates de minimis revenue from a Finacea foam royalty arrangement with LEO Pharma.

Product overview

VYNE Therapeutics is a clinical-stage biopharmaceutical company developing differentiated therapies for immuno-inflammatory conditions. The company's core technology is the proprietary InhiBET™ BET Inhibitor Platform, which includes two drug candidates: Repibresib (VYN201), a locally-administered pan-BD BET inhibitor gel for vitiligo, and VYN202, an oral BD2-selective BET inhibitor for immune-mediated diseases. VYNE is currently undergoing a merger with Yarrow Bioscience to shift focus toward autoimmune thyroid diseases, with the combined company planned to trade as Yarrow Bioscience under ticker YARW.

Differentiator

Problem solved

Functional benefit

Brands

• InhiBET: BET (bromo-domain and extra-terminal domain) inhibitor platform technology for developing therapies targeting immuno-inflammatory diseases.

Products and services

• Repibresib (VYN201) Locally administered pan-BD BET inhibitor designed as a 'soft drug' for diseases involving multiple inflammatory cell signaling pathways with low systemic exposure; lead indication is nonsegmental vitiligo.
• VYN202 Oral small molecule BD2-selective BET inhibitor designed for class-leading BD2 vs BD1 selectivity, maximum potency against BD2, and optimized oral bioavailability; in development for plaque psoriasis and other immune-mediated diseases.

Quantifiable outcome

• Phase 2b vitiligo trial: Repibresib 3% showed -43.6% change from baseline in F-VASI vs -25.6% for vehicle (p=0.0020)
• +1 more outcomes

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Four partnerships are on record, tiered core, minor and major.

• Yarrow BiosciencecoreStrategic or Co-development Partner · 17 December 2025VYNE agreed to merge with Yarrow Bioscience in an all-stock transaction valued at approximately $200 million. Following closing, the combined company will focus on advancing YB-101, a potentially first-in-class anti-TSHR antibody for Graves' disease and thyroid eye disease. Pre-closing financings of approximately $200 million led by RTW Investments are expected to fund operations into 2028.
• LEO PharmaminorChannel Partner/ Reseller/ DistributorVYNE previously licensed rights to Finacea foam to LEO Pharma A/S. VYNE receives royalty revenue from this agreement, generating approximately $0.2 million per quarter.
• Changchun GeneScience Pharmaceutical Co., Ltd (GenSci)majorStrategic or Co-development PartnerGenSci is conducting a Phase 1 trial evaluating YB-101 in patients with thyroid eye disease (TED) in China. Yarrow executed an exclusive license agreement with Shanghai Scizeng Medical Technology Co., Ltd (an affiliate of GenSci) to obtain global ex-China rights to develop GS-098 in Graves' disease and TED.
• Tay Therapeutics LimitedcoreTechnology or IntegrationVYNE licensed VYN201 and VYN202 from Tay Therapeutics Limited. The VYN202 License Agreement involved a one-time cash payment of $3.75 million in April 2023, with additional development milestone payments including $1.0 million upon initiation of Phase 2b trial for VYN201 and $1.0 million upon initiation of Phase 1a SAD/MAD trial for VYN202.

Scale indicators9 records

Recent moves6 records

Expansion highlights5 records

Market position

Competitive moat3 records

Key risks5 records

Key highlights6 records

Customer concentration

• Xx.com/VYNEtx

Revenue estimate

Valuation estimate

Number of profiles

Profiles10 records

Funding overview

Funding rounds6 records

Investors18 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about VYNE Therapeutics